drugset / Trial / NCT01514370

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

NCT01514370

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective, monocentric, double blind, placebo controlled, two arm study. Curcumin is derived from the rhizomes of the plant Curcuma longa (common name, turmeric) belonging to the Zingiberaceae family found in South Asian countries, especially India which is the largest producer. BCM95 (bioCurcumin) is a combination of a Curcumin extract and oil to enhance the bio-absorbability in humans. BCM95 may enhance and prolong the antioxidant and anti-inflammatory effects of the standard therapy maintaining a good safety profile.

Timeline

Start
2012-04-30
Primary completion
2016-03-31
Completion
2016-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 500 mg Oral
Background IFN beta-1a Protein / enzyme biologic 44 ug Subcutaneous

Indications